Literature DB >> 2565229

Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant.

D M Rock1, R L Macdonald, C P Taylor.   

Abstract

Zonisamide is a novel anticonvulsant that prevents seizures in laboratory animals and in man. Zonisamide (3 micrograms/ml and above) blocked the sustained firing of action potentials induced by depolarizing steps of current injected across the membrane of intracellularly recorded spinal cord neurons. Responses to GABA and glutamate were not altered by zonisamide, and spontaneous synaptically evoked activity was not reduced until higher concentrations of zonisamide (10 micrograms/ml) were applied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565229     DOI: 10.1016/0920-1211(89)90041-7

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  14 in total

1.  Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

Authors:  Hironori Yokoyama; Ryohei Yano; Hayato Kuroiwa; Tatsuya Tsukada; Hiroto Uchida; Hiroyuki Kato; Jiro Kasahara; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

Review 2.  Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

3.  T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.

Authors:  Adrian Handforth; Gregg E Homanics; Douglas F Covey; Kathiresan Krishnan; Jae Yeol Lee; Kenji Sakimura; Fredricka C Martin; Arnulfo Quesada
Journal:  Neuropharmacology       Date:  2010-06-12       Impact factor: 5.250

Review 4.  Low threshold T-type calcium channels as targets for novel epilepsy treatments.

Authors:  Kim L Powell; Stuart M Cain; Terrance P Snutch; Terence J O'Brien
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

5.  Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.

Authors:  Hironori Yokoyama; Ryohei Yano; Hayato Kuroiwa; Tatsuya Tsukada; Hiroto Uchida; Hiroyuki Kato; Jiro Kasahara; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-10-19       Impact factor: 3.584

Review 6.  Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Zonisamide decreases ethanol intake in rats and mice.

Authors:  Clifford M Knapp; Melissa Mercado; Tara Lynn Markley; Steven Crosby; Domenic A Ciraulo; Conan Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

8.  Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction.

Authors:  J C Martínez-Ávila; A García Bartolomé; I García; I Dapía; Hoi Y Tong; L Díaz; P Guerra; J Frías; A J Carcás Sansuan; A M Borobia
Journal:  Metabolomics       Date:  2018-05-09       Impact factor: 4.290

Review 9.  Early investigational drugs for hearing loss.

Authors:  Debashree Mukherjea; Sumana Ghosh; Puspanjali Bhatta; Sandeep Sheth; Srinivasan Tupal; Vikrant Borse; Thomas Brozoski; Kelly E Sheehan; Leonard P Rybak; Vickram Ramkumar
Journal:  Expert Opin Investig Drugs       Date:  2014-09-22       Impact factor: 6.206

10.  Zonisamide - a review of experience and use in partial seizures.

Authors:  Angus A Wilfong; L James Willmore
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.